Objective
To evaluate if anti-Müllerian hormone (AMH) is associated with pregnancy loss.
Design
A prospective cohort study within a block-randomized, double-blind, placebo-controlled trial of low dose aspirin.
Setting
Four U.S.A. clinical sites (2006-2012).
Patients
Women (n=1228) were aged 18-40 years with a history of one to two pregnancy losses and were actively attempting pregnancy without fertility treatment.
Interventions
None.
Main Outcome Measures
Pregnancy loss.
Results
Relative risks (and 95% CI) of hCG detected and clinical pregnancy loss were assessed using log binomial models with robust variance and inverse probability weights adjusted for age, race, BMI, income, trial treatment assignment, parity, number of previous losses, and time since most recent loss. AMH levels were defined as: low (<1.00 ng/mL) (n=124), normal (referent; 1.00 to 3.5 ng/mL) (n=595), and high (>3.5 ng/mL) (n=483). Of the 1202 women with baseline AMH data, 19 (17.3%) women with a low AMH experienced a clinical loss, compared to 61 (11.4%) with normal AMH and 50 (11.8%) with a high AMH level. Low or high AMH levels relative to normal AMH (referent) were not associated with clinical loss (Low AMH: RR, 1.13, 95% CI 0.74, 1.72; High AMH: RR 1.13, 95% CI 0.82, 1.56). Results for hCG detected pregnancy loss mirrored those of clinical loss.
Conclusions
AMH values were not associated with hCG detected or clinical pregnancy loss in unassisted conceptions in women with a history of one to two prior losses. Our data do not support routine AMH testing for prediction of pregnancy loss.